These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 21733757

  • 41. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J, Kalinowska-Łyszczarz A.
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [Abstract] [Full Text] [Related]

  • 42. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
    Sormani MP, Bonzano L, Roccatagliata L, De Stefano N.
    Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
    [Abstract] [Full Text] [Related]

  • 43. Will the newer oral MS agents be welcomed by managed care organizations?
    Lipsy RJ.
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S227-33. PubMed ID: 20873947
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.
    Niezgoda A, Losy J, Mehta PD.
    Folia Morphol (Warsz); 2001 Aug; 60(3):225-8. PubMed ID: 11552664
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C, García-Merino JA, Saiz A, Rodríguez-Antigüedad A, Álvarez-Cermeño JC, Estrada-Pérez V, Izquierdo G, Fernández O.
    Rev Neurol; 2019 Dec 17; 69(s02):1-9. PubMed ID: 31933293
    [Abstract] [Full Text] [Related]

  • 49. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED.
    CNS Drugs; 2018 Aug 17; 32(8):785-796. PubMed ID: 30105527
    [Abstract] [Full Text] [Related]

  • 50. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K.
    J Neurol Neurosurg Psychiatry; 2018 Dec 17; 89(12):1266-1271. PubMed ID: 29991490
    [Abstract] [Full Text] [Related]

  • 51. Two New Drugs Approved for Multiple Sclerosis.
    Aschenbrenner DS.
    Am J Nurs; 2019 Jul 17; 119(7):22-23. PubMed ID: 31232771
    [No Abstract] [Full Text] [Related]

  • 52. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 17; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 53. [Cladribine in the treatment of relapsing multiple sclerosis].
    Robles-Cedeno R, Ramio-Torrenta L.
    Rev Neurol; 2018 Nov 01; 67(9):343-354. PubMed ID: 30350846
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Update of the treatment of multiple sclerosis].
    Miyamoto K.
    Nihon Rinsho; 2013 May 01; 71(5):817-21. PubMed ID: 23777088
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J.
    Proc Natl Acad Sci U S A; 1996 Feb 20; 93(4):1716-20. PubMed ID: 8643695
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. The cladribine trial in secondary progressive MS: response.
    Goodin DS.
    Neuroepidemiology; 2000 Feb 20; 19(1):53-4. PubMed ID: 10654289
    [No Abstract] [Full Text] [Related]

  • 60. [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].
    Hartung HP, Kieseier BC, Aktas O.
    Nervenarzt; 2010 Feb 20; 81(2):194-202. PubMed ID: 20127230
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.